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BACKGROUND: Breast cancer diagnosis may be a teachable moment for lifestyle behaviour change and to prevent adjuvant
therapy associated weight gain. We assessed the acceptability and effectiveness of two weight control programmes initiated
soon after breast cancer diagnosis to reduce weight amongst overweight or obese women and prevent gains in normal-weight
women.
METHODS: Overweight or obese (n= 243) and normal weight (n= 166) women were randomised to a three-month unsupervised
home (home), a supervised community weight control programme (community) or to standard written advice (control). Primary
end points were change in weight and body fat at 12 months. Secondary end points included change in insulin, cardiovascular risk
markers, quality of life and cost-effectiveness of the programmes.
RESULTS: Forty-three percent of eligible women were recruited. Both programmes reduced weight and body fat: home vs. control
mean (95% CI); weight −2.3 (−3.5, −1.0) kg, body fat −1.6 (−2.6, −0.7) kg, community vs. control; weight −2.4 (−3.6, −1.1) kg,
body fat −1.4 (−2.4, −0.5) kg (all p < 0.001). The community group increased physical activity, reduced insulin, cardiovascular
disease risk markers, increased QOL and was cost-effective.
CONCLUSIONS: The programmes were equally effective for weight control, but the community programme had additional
benefits.
CLINICAL TRIAL REGISTRATION: ISRCTN68576140
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BACKGROUND
Observational studies indicate that excess weight at breast cancer
(BC) diagnosis and significant weight gain (5–10%) thereafter are
associated with increased BC specific and all-cause mortality1–4
greater side effects of treatment5,6 and decreased quality of life
(QOL).7 Significant numbers of BC patients are overweight (30%)
or obese (25%) at diagnosis8 and gain ≥ 5% weight thereafter
(30–50%).9 These data suggest that weight loss in overweight/
obese women and preventing weight gain in all patients could
improve the outcome and wellbeing of women after a diagnosis
of BC. A large number of trials amongst overweight or obese BC
patients after diagnosis report that weight loss is feasible and
safe10,11 however, nearly all of these were initiated long after
completion of adjuvant treatment, and after the weight gain
associated with diagnosis and treatment had occurred.10,11 Three
small randomised studies demonstrate the feasibility and reason-
able compliance of weight and exercise programmes based either
on clinic visits or telephone interventions during chemotherapy
soon after BC diagnosis.12–14
More detailed studies of body composition amongst patients with
BC suggest that weight-related adverse effects are specifically
associated with increased adiposity and reduced fat-free mass.15–17
Early initiation of weight control is an opportunity prevent
deleterious weight gain, gains in fat and reduced fat-free mass
which may occur during adjuvant treatment in the months after
diagnosis.18 There is a potential teachable moment at diagnosis thus
engagement in lifestyle behaviour change soon after diagnosis may
be more effective than further down the line after diagnosis.19,20
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Both home and supervised community programmes have been
found to be effective for behaviour change in the post-treatment
setting.10,11 The aim of the study reported here was to compare
the acceptability and effectiveness of both types of intervention
compared with a control group. We compared a 3-month home
phone and mail programme versus a community programme with
a control group receiving standard written advice. The interven-
tions were initiated soon after diagnosis, either before or early
into adjuvant treatment programmes. The weight control
programmes aimed to limit gains in body fat to ≤ 1 kg over
the year amongst normal-weight women (body mass index, BMI
< 25 kg/m2), and achieve a gradual weight loss of ≥ 5% (i.e. a
reduction in body fat of ≥ 3 kg) amongst women who were
overweight or obese at diagnosis (BMI ≥ 25 kg/m2). Primary end
points were change in weight, body fat and fat-free mass (FFM)
at 12 months. Secondary end points included 12-month change
in cardiovascular (CVD) markers, insulin sensitivity (homoeostatic
model assessment, HOMA), QOL, fitness, and the relative cost-
effectiveness of the programmes. We also wished to assess
the generalisability of the programme and thus women were




A multicentre randomised controlled three-arm trial (1:1:1) within
nine breast units in the Greater Manchester and Cheshire Cancer
Research Network, UK, coordinated by Manchester University NHS
Foundation Trust at Wythenshawe Hospital.
Patient population
Participants were recruited within 12 weeks of surgery for invasive
or in-situ primary BC. There were no age, weight or treatment
restrictions since we were assessing the general applicability of
the interventions in all patients diagnosed with early BC. Women
were excluded if they had major physical/psychiatric conditions
which would limit compliance to a diet and physical activity (PA)
programme, diabetes requiring insulin or regularly taking
medication known to affect body composition, e.g. daily
glucocorticoids or were treated with neoadjuvant chemotherapy
or endocrine therapy. Women were made aware of the trial before
surgery or at their initial post-surgery appointment by their breast
surgeon or research nurse.
Randomisation and stratification
Randomisation was undertaken in the main recruiting breast unit
at Wythenshawe Hospital using a minimisation programme by the
trial administrator and was stratified by; chemotherapy or no
chemotherapy, BMI ≥ or < 27 kg/m2, axillary node clearance (ANC)
versus no ANC, and breast unit.
Study interventions
Standard written advice (‘control’). This group received a com-
prehensive booklet which explained the importance of weight
control (i.e. ≥ 5% weight loss in overweight/obese and prevention
of weight gain in normal-weight subjects) and physical activity
(PA) after diagnosis for overall health and wellbeing, and the
possible effects on BC outcome. It recommended a healthy
Mediterranean type diet (45% energy from low glycaemic index
carbohydrates, 30% from fat, 15% monounsaturated, 7% from
saturated, 8% from polyunsaturated fat, 25% from lean protein
foods, 5–7 portions fruit and vegetables/day) as described
previously,21,22 at least 150 min/week of moderate intensity
aerobic PA, two sessions of resistance PA per week and arm
mobility exercise in accordance with national guidelines,23 and
standard advice for dealing with gastrointestinal and fatigue side
effects for women receiving chemotherapy.
Home-based phone and mail programme (‘home’). This group
received the written advice described above and individualised
diet and PA advice from one of the trial dietitians and the physical
activity specialist mainly by telephone after an initial face to face
consultation. Diet advice included individualised food portion lists
to follow a Mediterranean diet to meet estimated energy
requirements for weight maintenance or an energy restriction
25% below estimated energy requirements for weight loss as
described previously.22 Physical activity advice promoted a
gradual increase towards the above targets for aerobic, resistance
and arm mobility exercises which were tailored to the individual.
Women were asked to estimate and report the intensity of PA
using the rate of perceived exertion scale.24 Initial advice was
given face to face in the main recruiting breast unit at
Wythenshawe Hospital. The intensive 12 weeks of the programme
included six fortnightly 20-min phone calls from their allocated
trial dietitian to check compliance to diet and PA targets and
address individual problems. This was followed by a mailed
summary of goals and recommendations discussed. Women also
received six fortnightly mailings which covered the same issues as
the community programme. These were received on the weeks
between the calls to maintain weekly contact throughout the 12-
week programme (Supplementary Table 1).
Supervised community-based group programme (‘community’).
This group received identical written and face to face advice as
the ‘home’ group, but were also asked to attend 12 weekly PA and
dietary education sessions in one of five different community
locations across Greater Manchester. Each session included 30min
of moderate intensity aerobic PA and 10min of resistance and
flexibility PA, followed by a 30-min diet and behaviour change
education session (Supplementary Table 1). Women were
monitored throughout the class to ensure that they were
exercising at a moderate level (50–80% age-adjusted heart rate
maximum by pulse checks and rating of perceived exertion). In
addition, women were asked to undertake four aerobic and one
resistance PA sessions/week at home to meet their weekly goals.
The home and community programmes used established
behavioural techniques, i.e. goal setting, self-monitoring of weight
and waist (weekly), diet (6 monthly food diaries), PA (daily
pedometer), stress and time management, relapse prevention,
and overcoming barriers.25 Both groups received booster phone
calls from their allocated dietitian to reinforce advice, problem
solve and monitor compliance at 4, 6 and 9 months. All study
participants including the control group received a three month
trial newsletter to encourage retention to the trial.
Outcome measures
Trial assessments were conducted in the main recruiting breast
unit at Wythenshawe Hospital at baseline, 6 and 12 months. Body
weight, height, waist and hip circumference, blood pressure,
fasting insulin, glucose, HOMA, total, LDL and HDL cholesterol and
triglycerides were assessed and estimated using standard
methods as described previously.21,22,26 Body fat, FFM (body mass
excluding fat mass and bone mineral content) and trunk fat were
determined from supine dual energy X-ray absorptiometry (DXA)
scans (Hologic Discovery A with Hologic APEX software). Data
from the head were excluded from all DXA measures due to the
high proportion of bone mineral content known to affect the
accuracy of soft‐tissue measures. Unilateral artefacts, i.e. metallic
joint replacements, breast implants and lymphoedema were
adjusted for by replacing the corresponding contralateral value.
Physical/functional capacity was assessed from a 12min treadmill
walking test.27 Quality of life was assessed with the Functional
Assessment of Cancer Therapy (FACT) physical wellbeing (PWB),
functional wellbeing (FWB), BC specific (BCS), endocrine (ESS) and
fatigue (FSS) sub scales reported as the trial outcome indicator
(TOI) summary scores, e.g. TOI breast cancer (TOI-BC)= PWB+
The effectiveness of home versus community-based weight control. . .














FWB+ BCS; TOI endocrine symptoms (TOI-ES)= PWB+ FWB+
ESS; TOI fatigue (TOI-F)= PWB+ FWB+ FSS.28
Adherence at 6 and 12 months
Dietary adherence at 6 and 12 months was assessed from seven-
day food diaries in all women and analysed using WISP version 3
(Tinuviel Software, Anglesey, Wales) and levels of moderate and
vigorous PA were assessed from the Scottish Physical Activity
Questionnaire.29
Economic evaluation
Patient-specific costs were estimated for the three trial arms from
patient self-reported health care resource use diaries completed
every 3 months and hospital records (hospitalisations, medication,
outpatient visits, GP services used, etc) up to 12-months post-
randomisation. These data were combined with EQ-5D-3L tariffs
collected at baseline, 3, 6 and 12 months to estimate cost-utility.30
The three interventions were compared in terms of their mean
total costs and Quality Adjusted Life Years (QALYs) and the
incremental cost-effectiveness ratios (ICER) were estimated. This
describes the incremental change in costs divided by the
incremental change in health outcome. The ICER is compared
against the cost-effectiveness threshold. This threshold reflects the
maximum amount society is willing to pay for an additional unit of
health gain. In the UK, the cost-effectiveness threshold lies
between £20,000 and £30,000 per QALY.31
Statistics
The sample size of 131 subjects/group was chosen to detect a 3 kg
difference in change in body fat measured with DXA (assuming a
common SD of 7.6 kg) between the three groups at 12 months
with a two-sided significance level of 2% to adjust for multiple
testing. The primary analysis was an intention to treat comparison
of body fat and weight between the three groups defined at
randomisation. Secondary pre-defined analyses compared body
fat and weight at 6 and 12 months in the three groups stratified
by whether subjects were normal weight or overweight/obese at
baseline and receiving or not receiving adjuvant chemotherapy.
*Screening figures from the main recruiting site (Wythenshawe Hospital) only
Assessed for eligibility (n = 1116)*
Excluded (n = 816)*
Not meeting inclusion criteria (n = 410)
Breast cancer-related issues, e.g., neoadjuvant 
treatment or metastases (n = 160)
Comorbidities (n = 157)
Recruitment issues, e.g., unable to contact 
within given time frame, language barriers
(n = 80)
Unknown reason (n = 13)
Declined to participate (n = 406)
Factors related to trial recruitment soon after 
diagnosis, e.g., does not want extra hospital 
visits, blood sample or scans (n = 173)
Does not want to be in a research trial, e.g., has 
too many other commitments (n = 129)
Diet and/or exercise related, e.g., already has a 
healthy lifestyle according to participant (n = 24)
Reason not disclosed (n = 80)
12 months (n = 122)
Lost to follow-up, reasons:
recurrence of breast cancer 
(n = 3)
Other health problems (n = 5)
Request to withdraw (n = 2)
Loss of contact (n = 1)
Family issues (n = 3)
6 months (n = 133)
Missed study visit (n = 3)
Lost to follow-up, reasons:
other health problems (n = 1)
Request to withdraw (n = 1) 
Control (n = 138)
received allocated 
intervention (n = 138)
6 months (n = 136)
Lost to follow-up, reasons:
other health problems (n = 1)
Home programme (n = 134)
received allocated
intervention (n = 134)
Allocation
Randomised (n = 409)
Enrolment
Community programme (n = 137)
received allocated
intervention (n = 137)
6 months (n = 132)
Lost to follow-up reasons:
other health problems (n = 1)
Loss of contact (n = 1)
Analysed (LOCF) n = 138
12 months (n = 118)
Lost to follow-up, reasons:
recurrence of breast cancer 
(n = 2)
Other health problems (n = 1)
Request to withdraw (n = 3)
Loss of contact (n = 5)
Family issues (n = 2)
RIP (n = 1)
12 months (n = 130)
Lost to follow-up, reasons:
recurrence of breast cancer 
(n = 1)
Other health problems (n = 1)
Request to withdraw (n = 2)
Loss of contact (n = 1)
Pregnancy (n = 1)
Analysed (LOCF) n = 134 Analysed (LOCF) n = 137
Follow-up
Analysis
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow diagram of patients recruited to the B-AHEAD trial. *Screening figures are
from the main recruiting site (Wythenshawe Hospital) only
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We also assessed changes in secondary end points (insulin, HOMA,
CVD risk markers, QOL, fitness) between the groups.
Outcomes at 6 and 12 months were analysed using analyses of
variance regression models (ANCOVA) incorporating baseline
measures as covariates. Specific pairwise comparisons between
groups were carried out using Scheffe’s multiple comparison tests.
The last observation carried forward (LOCF) method was used for
missing outcome data. This is a conservative estimate of the ‘non-
random’ missing data, as nonattendance at clinic appointments is
considered more likely for those who gained weight.
RESULTS
Four hundred and nine women were randomised between August
2008 and February 2011, representing 42% of eligible patients
from Wythenshawe Hospital which supplied complete recruitment
data as reported previously.32 Women were randomised on
average 55 (IQR 39–68) days from the date of their breast surgery.
Sixteen of the control (11.5%), 16 of the home (12%) and 7 of
the community group (5%) withdrew from the study due to
recurrence of breast cancer (n= 6), other health problems (n=
10), family issues (n= 5), pregnancy (n= 1), request to withdraw
(n= 8), patient had died (n= 1) and loss of contact (n= 8) (Fig. 1).
At baseline, the three groups were comparable for age, ethnicity,
BMI, menopausal status, tumour characteristics, breast surgery, BC
treatments and prevalence of co-morbidities, and index of
multiple deprivation (Table 1). Fifty-nine percent of the overall
cohort were overweight or obese and 41% normal weight. Thirty-
eight percent received adjuvant chemotherapy (56% overweight/
obese and 44% normal weight). Women who withdrew were of
comparable BMI to women who remained in the study, mean (SD)
27.3 (5.5) vs. 27.2 (5.4) kg/m2 P= 0.923, but were significantly
younger, 51 (9.0) vs. 55 (10.4) years (P= 0.019) and more likely to
be receiving chemotherapy, 13.5% of the chemotherapy group vs.
7.1% of the no chemotherapy group (P= 0.025).
Participation in the home and community group programmes
During the initial 12-week phase of the programmes, women in
the home group received mean (interquartile range) 85 (83–100) %
of their six scheduled home phone calls and were sent 100%
of the mailings, whilst women in the community group
attended 64 (50–75)% of the 12 scheduled weekly group classes.
Four- and nine-month booster calls were received respectively by
84 and 80% of the home and 83 and 82% of the community
groups.
Primary end points: change in weight and body composition
DXA data were analysed from 389 participants; 4 had no DXA
scan and 16 had their DXA data omitted as they had bilateral high-
Table 1. Baseline characteristics of patients randomised to the
three groups
Control Home Community
(n= 138) (n= 134) (n= 137)
Age (years) 55.3 (10.5) 54.6 (11.2) 54.0 (9.2)




58 (42.0%) 50 (37.3%) 55 (40.1%)
Overweight (≥ 25–29.99 kg/m2) 38 (27.5%) 56 (41.8%) 49 (35.8%)
Obese (≥ 30 kg/m2) 42 (30.4%) 28 (20.9%) 33 (24.1%)
Pre/peri-menopausal 56 (40.6%) 55 (41.0%) 49 (35.8%)
Post-menopausal 82 (59.4%) 79 (59.0%) 88 (64.2%)
Days between final breast
surgery and randomisation
50 (39–68) 55 (36–66) 54 (40–68)
Current smoker 15 (10.9%) 17 (12.7%) 9 (6.6%)
Ethnicity
White 132 (95.7%) 126 (94.0%) 129 (94.2%)
Black 2 (1.4%) 4 (3.0%) 4 (2.9%)
Asian 3 (2.2%) 4 (3.0%) 3 (2.2%)
Mixed 1 (0.7%) 0 (0.0%) 1 (0.7%)
Social circumstances
Married or cohabiting 106 (76.8%) 94 (70.0%) 102 (74.5%)
Educated to degree level
or higher
64 (46%) 59 (44%) 67 (49%)
Index of multiple deprivation
Greater Manchester Quintile
1 (least deprived) 66 (47.8%) 46 (34.3%) 48 (35.0%)
2 28 (20.3%) 31 (23.1%) 31 (22.6%)
3 15 (10.9%) 26 (19.4%) 24 (17.5%)
4 12 (8.7%) 15 (11.2%) 17 (12.4%)
5 (most deprived) 17 (12.3%) 16 (11.9%) 17 (12.4%)
Co-morbidities
Respiratory, e.g. asthma, COPD 19 (13.8%) 15 (11.2%) 15 (10.9%)
Psychiatric, e.g. anxiety,
depression
14 (10.1%) 16 (11.9%) 19 (13.9%)
Cardiovascular disease 12 (8.6%) 10 (7.4%) 11 (8.0%)
Arthritis, back or joint
problems
41 (29.0%) 32 (24.0%) 29 (21.6%)
Type 2 diabetes 3 (2.2%) 7 (5.2%) 4 (2.9%)
Previous breast cancer 8 (5.8%) 7 (5.2%) 3 (2.2%)
Tumour characteristics
DCIS/LCIS 13 (9.4%) 18 (13.4%) 18 (13.2%)
Invasive tumour Grade 1 25 (18.0%) 23 (17.2%) 21 (15.3%)
Invasive tumour Grade 2 61 (44.2%) 56 (41.8%) 62 (45.3%)
Invasive tumour Grade 3 40 (28.9%) 38 (28.4%) 34 (24.8%)
Surgery
Mastectomy 45 (32.6%) 47 (35.1%) 48 (35.0%)
Axillary node clearance (ANC) 34 (24.6%) 34 (25.4%) 33 (24.1%)
Screen detected breast cancer 52 (51.0%) 53 (54.6%) 61 (60.4%)
Adjuvant treatment a
Chemotherapy 52 (37.7%) 52 (38.8%) 51 (37.2%)
Anthracycline only 29 (21.0%) 33 (24.6%) 27 (20.0%)
Anthracyline & taxane 23 (16.7%) 19 (14.2%) 24 (17.5%)
Radiotherapy 98 (71.0%) 91 (67.9%) 104 (75.9%)
Herceptin 19 (13.8%) 13 (9.7%) 11 (8.0%)
Table 1 continued
Control Home Community
(n= 138) (n= 134) (n= 137)
Tamoxifen 68 (49.3%) 75 (56.0%) 78 (56.9%)
Aromatase inhibitor 36 (26.1%) 34 (25.4%) 34 (24.8%)




5 (3.6%) 10 (7.5%) 8 (5.8%)
BMI body mass index, COPD chronic obstructive pulmonary disease, DCIS
ductal carcinoma in situ, LCIS lobular carcinoma in situ
Mean (SD) n (%) median (interquartile range)
aPatients were recruited between September 2008 and November 2010
The effectiveness of home versus community-based weight control. . .
M Harvie et al.
4
density artefacts. At 12 months the home and community groups
both significantly reduced weight and body fat whilst these
increased in the control group. Weight reduction in the home
group compared with controls was mean (95% confidence
interval) −2.3 (−3.5, −1.0) kg, and body fat reduction was −1.6
(−2.6, −0.7) kg (Table 2). Weight reduction in the community
group compared with controls was −2.4 (−3.6, −1.1) kg, and body
fat reduction was −1.4 (−2.4, −0.5) kg (all p < 0.001). There were
small but statistically significant reductions in FFM in the home
and community groups and a modest increase in the control
group. The control group experienced gains in weight and body
fat between 6 and 12 months, whilst the home and community
groups respectively maintained or had further reductions of
weight in this period which was 3–9 months after the initial
intensive 12-week programme (Table 2).
Pre-specified subgroup analyses indicated that weight and
body composition results differed according to BMI category
and whether patients were treated with chemotherapy (Table 3,
Fig. 2). Both programmes induced weight loss amongst over-
weight/obese women who were not receiving chemotherapy,
whilst weight was maintained in controls. However, the
programmes did not induce weight loss amongst overweight/
obese patients who were receiving chemotherapy for whom
weight was maintained.
Both programmes prevented weight gain amongst normal-
weight women who were not receiving chemotherapy, whilst
weight increased in controls. In contrast, the programmes did not
prevent weight gain amongst normal-weight women receiving
chemotherapy. In this normal weight group, patients receiving
chemotherapy gained comparable amounts of weight to the non-
chemotherapy patients at 12 months (Table 3, Fig. 2).
Changes in body fat were comparable to changes in weight in
these subgroups. Overweight/obese non-chemotherapy patients
experienced small reductions in FFM alongside weight loss, whilst
FFM was maintained in the overweight/obese chemotherapy
group and the chemotherapy and non– chemotherapy normal
weight sub groups (Table 3).
Secondary end points
Biochemistry: The community and home groups were similar with
respect to weight control but significant reductions in total and
LDL cholesterol, systolic blood pressure, serum insulin, HOMA, and
triglycerides at 12 months were only detected in the community
group (Table 4). The home group had smaller reductions in these
parameters which were not significantly different from controls.
Distance walked on the 12-minute walk test (a measure of fitness)
increased above baseline in all groups. At 6 months the
community group had significantly greater increases compared
to the controls and home groups. The difference between the
groups was attenuated at 12 months.
Quality of life: There were numerical improvements in the scores
for QOL (FACT TOI for fatigue, endocrine symptoms and BC) in all
three groups at 6 and 12 months. The improvement reached
significance using the FACT TOI BC at 6 and 12 months for the
community group compared with controls (both p < 0.05) but not
the home group compared with controls (Table 4).
Changes in dietary intake and physical activity: All three groups
reduced energy intake (Supplementary Table 2). The greatest
numerical reductions were reported by the home group; mean
(95% CI) difference in the home vs. control group was −153
(−239, −68) kcal/day (P= 0.001) at 6 months and −161 (−261,
−61) kcal/day at 12 months (p < 0.001), whilst mean (95% CI)
difference in energy intake in the community vs. control group
was −82 (−185,+ 20) kcal/day at 6 months (P= 0.166) and −107
(−205, −9) kcal/day at 12 months (P= 0.027). Reported levels of
PA increased in all three groups over the year (Supplementary
Table 2). At 12 months the community group had significantly
greater increases compared to the control and home groups;
mean (95% CI) difference community vs. control 119 (6, 230)
minutes/week (P= 0.035) and mean (95% CI) difference commu-
nity vs. home group 151 (36 to 265) minutes/week (P= 0.005).
Economic evaluation. Disaggregated and mean total health
care costs and mean QALYs of the three interventions are
reported in Supplementary Tables 3 and 4. The home group
Table 2. Changes in weight and body composition at six and twelve months for the overall cohort
Change over timea Group differenceb
Control Home Community Home vs Control Community vs Control Community vs Home













































































































aANCOVA, Mean (95% CI)
bANCOVA with Bonferroni adjustment, Mean (95% CI)
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(£7737) and the community group (£7914) had reduced patient
costs compared with the control group (£8547) mainly related to
decreased usage of medications to treat treatment toxicity, e.g.
granulocyte-colony stimulating factor (GCSF) used in chemother-
apy patients who had become neutropenic, decreased accident
and emergency visits and physiotherapy contacts. The three
interventions had equivalent QALY scores of ~0.8. Comparing the
difference in costs and difference in effects between the home
and community groups gives an incremental cost-effectiveness
ratio (ICER) of £9381.45. For a threshold of £20,000 per QALY there
is a 52% probability that the community group is cost-effective;
this increases to 60% for a £30,000 per QALY threshold
(Supplementary Fig. 1).
DISCUSSION
The three-month dietary and PA weight control programmes
initiated soon after surgery produced sustained weight reduction
in overweight women and prevented weight gain in normal-
weight women during the 12 months of the study. Although
equally effective for weight control, the community programme
was more effective for increasing PA, whilst the home programme
appeared more effective for dietary change and reducing energy
intake. The greater PA in the community group probably accounts
for the greater reductions in insulin, lipids33 and blood pressure,34
and improvements in fitness and QOL.35 Neither programme was
effective for inducing weight loss or preventing weight gain
amongst patients receiving chemotherapy.
Long term behaviour change is pivotal to the effectiveness of
any weight control programme. Beneficial changes in diet and PA
behaviours, weight, CVD disease biomarkers, and QOL were
observed at 12 months, i.e. 9 months after completion of the initial
3-month phone and community programmes. Some evidence
suggests that uptake of interventions and maintenance of
behaviours within studies are greater when were commenced
nearer to the time of diagnosis compared with those initiated later
although there are no randomised trials comparing early versus
later interventions.36 Few studies have assessed the maintenance
of diet and PA behaviour change and weight loss beyond the end
of the intervention.36 The respective maintained and continued
weight loss in the home and supervised programmes between 6
and 12 months (i.e. 3–9 months after the intensive 12-week
intervention) is an important finding. Both groups did receive
minimal ongoing contact via booster calls at 4 and 9 months. This
ongoing albeit minimal contact is likely to have contributed to
their maintained lifestyle behaviour change. Average weight loss
in the overweight/obese non-chemotherapy patients was 3 kg
(4%) when assessed 9 months after the end of the active
intervention. This compares favourably with reported 12-month
weight loss at the end of a 12-month active intervention amongst
women who joined the programmes 9–60 months after diagnosis
summarised by Chlebowski and Reeves et al. which ranged from
3.7–5 kg (4–5%).10 This level of weight loss may be clinically
important for BC patients. A large randomised trial of low-fat
dietary intervention (Women’s Intervention Nutrition Study,
WINS)37 reported a 24% reduction in relapse where women lost
on average 2.3 kg (3%).
Home based home diet and PA programmes have been shown
to be equivalent to face to face versions for weight loss amongst
BC patients after adjuvant treatment,38 and amongst other patient
groups.39,40 Home based mail and web programmes are effective
for changing diet and weight, but they only have limited effects
on PA as reported here.41 PA increases more within supervised
programmes42 as these overcome common barriers including
women’s concerns about safety and low self-efficacy for physical
activity.43 The independent effects of PA on toxicity44 and possibly
BC outcome45 mean that programmes need to impact on PA as
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programmes which include initial supervised PA sessions and
more intensive self-monitoring and feedback, which have proven
to successfully promote PA in home based CVD rehabilitation and
heart failure programmes.46,47
Weight gain was observed in the normal weight but not the
overweight controls which is consistent with previous reports in
the literature.18 The weight control advice was effective for
preventing these gains amongst patients who were not receiving
chemotherapy. It is important to note that none of the normal-
weight patients reduced weight to a BMI of < 18.5 kg/m2 and so
did not require weight gain advice.
Chemotherapy patients were keen to enter the programmes,
and were equally likely to attend the community sessions or
receive calls, but slightly more likely to drop out. Both
programmes appeared to confer some benefits to the chemother-
apy patients in terms of reduced costs of toxicity related
medication (e.g. GCSF) and accident and emergency admissions,
but they were ineffective for weight control during chemotherapy
and in the post-treatment phase up to 12 months. The limited
success of home12,13 and group48 weight control programmes
during adjuvant chemotherapy has been reported previously in
BC patients, with the exception of an intensive dietary interven-
tion which involved twice-weekly community cookery classes and
group meals.49 However, Goodwin et al. reported that women
who had previously received chemotherapy achieved comparable
successful weight loss to women who had not previously received
chemotherapy in a home-based phone weight loss programme
initiated at a median of 9 months from diagnosis and at least
1 month after completion of adjuvant chemotherapy.50 Future
studies should test modified, more achievable approaches
amongst chemotherapy patients, e.g. intermittent energy restric-
tion which is effective for weight loss in the non-cancer setting.51
The combined diet and PA community programme was the
most cost-effective. There are few data on the cost-effectiveness
of programmes amongst early BC patients.52 Two earlier studies
failed to demonstrate the cost-effectiveness of PA only pro-
grammes during adjuvant treatments which were home53 or
community54 based.
The strengths of this study include random allocation to the
three groups, DXA assessment of body composition, and
12 months follow up. We have previously reported the good
uptake to the trial and that our cohort is representative of newly
diagnosed early-stage BC patients,32 whilst the low drop-out
provides reliable follow up data without making assumptions
about missing data. We tested 12-week programmes. The
optimal length of programme for sustained behaviour change
for weight loss is not known. Some guidelines advocate a
minimum of 16 contacts over a 6-month period as used in the
Diabetes Prevention Programme,55 whilst others advocate a
minimum of 12 weeks.56 It is estimated to take 10 weeks to
form a habit.57 Both of our groups involved weekly contacts.
However, half of the contacts in the home-based group were
mailings rather than direct patient contact, hence this group had
reduced contact with their allocated dietitian which may have
limited the effectiveness of the programme. The reduced effects
on physical activity in the home-based group is likely to reflect
the home-based modality rather than the level of contact. Poor
collective results of home-based PA interventions have been
reported amongst patients with BC regardless of the length of
intensity of the intervention.58
Limitations include that the sample size may not be sufficiently
powered for the subgroup analyses in chemotherapy and non-
chemotherapy patients and the use of self-report rather than
objective measurements of PA such as accelerometry. Our metrics
for assessing adherence were based on retention to the study and
attendance to classes and receipt of the calls. Future studies
should evaluate more detailed adherence to the diet and PA
prescriptions which would give a more meaningful evaluation of
engagement with the programmes.
We have shown significant numbers of BC patients are
interested and motivated to enter and adhere to home and
community-based diet and PA weight control programmes soon
after diagnosis. Lifestyle programmes in current oncology practice
are mainly focussed at the end of active treatment.59,60 This has
been identified as a time of need amongst patients,61 but it means
that programmes are initiated after women may have already
gained weight as a result of the psychological and physical effects
of BC diagnosis and treatment. Research should focus on
developing cost-effective interventions for women soon after
diagnosis to utilise this potential teachable moment. Such
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p = or < 0.001 p = or < 0.01 p = or < 0.05
Fig. 2 Changes in weight in overweight/ obese, normal weight and chemotherapy sub groups shown as mean 95% confidence intervals)
The effectiveness of home versus community-based weight control. . .
M Harvie et al.
8
Table 4. Changes in secondary end points over 12 months for the overall cohort
Change over timea Group differenceb
Control Home Community Home vs. Community vs. Community vs.
Control Control Home





















































































































































































































































































































































12 months 1.1 (−1.5, 3.8) −1.3 (−3.7, 1.1) −3.8 (−6.3, −1.3)
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programmes are likely to improve the future health of women
affected by BC by reducing future weight-related illness and
improving QOL. Ongoing randomised trials62 will inform the
potential effectiveness of weight control programmes for improv-
ing BC specific outcomes for BC patients long after diagnosis and
treatment.
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